September 14 2020
Protocol NRG-BN007, A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma (NCT 04396860)
NRG Oncology is currently enrolling to a new trial for patients with newly diagnosed MGMT unmethylated glioblastoma. NRG-BN007 is designed to determine if a combination of the immunotherapy drugs ipilimumab and nivolumab following radiotherapy can help improve progression-free survival (Phase II) or prolongs overall survival (Phase III) for patients with this type of brain tumor and tumor biomarker.
Glioblastomas are the most common and aggressive primary brain cancer in adults, which is almost universally fatal with a median survival of 18 months. Patients with glioblastoma and the unmethylated MGMT biomarker especially have a poor prognosis. Typically, patients with newly diagnosed MGMT unmethylated glioblastoma undergo surgery to remove the tumor, then radiotherapy, and the drug temozolomide. However, immunotherapy drugs such as ipilimumab and nivolumab have substantially improved cancer treatment outcomes in clinical trials for other types of cancer.
Learn more about this trial on ClinicalTrials.gov
Access the protocol documents and materials on CTSU.org